Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Fig. 3

Efficacy endpoints over time in the total population. American College of Rheumatology (ACR)20 (a); ACR50 (b); ACR70; (c); Disease Activity Score in 28 joints (DAS28)-4(erythrocyte sedimentation rate (ESR))<2.6 (d); mean Health Assessment Questionnaire-Disability Index (HAQ-DI) (e). Baseline values were those of the phase II or phase III index study. SE standard error

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us